Aurinia Pharmace Stock Price, News & Analysis

Aurinia Pharmaceuticals announced updated interim results from the AURORA 2 study of LUPKYNIS for lupus nephritis treatment. The findings show sustained safety and tolerability, with patients experiencing significant reductions in proteinuria at 30 months, while renal function remained stable. The study's results will be presented at the American College of Rheumatology Convergence 2021. LUPKYNIS is the first FDA-approved oral therapy for active lupus nephritis, fulfilling a critical need in treating this serious condition.

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) will release its third quarter 2021 financial results on November 3, 2021, before markets open. A management conference call is scheduled for 8:30 a.m. ET to discuss financial outcomes and operational updates. The company highlights its focus on delivering therapies for serious diseases, with its main product being LUPKYNIS™, the first FDA-approved oral therapy for active lupus nephritis in adults. Interested parties can access the call through a dial-in or an online webcast.

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) announced important data regarding LUPKYNIS™ (voclosporin) for treating lupus nephritis (LN). The findings will be presented at the virtual American Society of Nephrology Kidney Week 2021 (November 2-7) and the American College of Rheumatology Convergence 2021 (November 3-9). Key presentations include updated analyses from the AURORA 2 study, demonstrating LUPKYNIS's effectiveness and safety. Lupus nephritis affects 200,000-300,000 people in the U.S., with a heightened risk in Black and Hispanic populations.

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) announced participation in two upcoming virtual investor conferences. Management will present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 20, 2021, at 2:55 pm ET, and at the Cantor Global Healthcare Conference on September 30, 2021, at 12:40 pm ET. Interested parties can access webcasts via the Aurinia website, where replays will also be available. The company focuses on treating serious diseases with high unmet medical needs, notably introducing an FDA-approved therapy for lupus nephritis.

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) will present at the H.C. Wainwright & Co. 23rd Annual Global Investment Conference from September 13-15, 2021. The presentation will be available on-demand starting September 13, 2021, at 3 PM ET. Interested parties can access it via the Aurinia corporate website. The company specializes in biopharmaceuticals, particularly focusing on therapies for serious diseases with high unmet medical needs, and has recently launched the first FDA-approved oral treatment for adult lupus nephritis.

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) has announced the acquisition of two assets, AUR200 and AUR300, aimed at enhancing its pipeline for rare autoimmune and kidney diseases. AUR200, a recombinant protein targeting BAFF/APRIL, was acquired for $750,000, with further regulatory milestone payments expected. AUR300, a peptide therapeutic modulating M2 macrophages, was licensed for an upfront fee of $6 million, with additional milestone payments. Both programs aim to address unmet medical needs in immunology and nephrology, with clinical development anticipated for 2023.

Aurinia Pharmaceuticals (NASDAQ: AUPH) announced that its executive management team will participate in a fireside chat at the Virtual BTIG Annual Biotech Conference on August 10, 2021, at 2:50 p.m. ET. Interested parties can access the live webcast via the 'Investors' section on Aurinia's corporate website. Additionally, a replay will be provided. Aurinia is a biopharmaceutical company focused on therapies for serious diseases with high unmet medical needs, including its FDA-approved treatment, LUPKYNIS™ (voclosporin), for adult patients with active lupus nephritis.

Aurinia Pharmaceuticals (AUPH) reported its Q2 2021 financial results, showing significant growth due to the commercial launch of LUPKYNIS for lupus nephritis. Total revenue reached $6.6 million, a sharp increase from $29,000 in Q2 2020. The company anticipates annual net revenue of $40 to $50 million for LUPKYNIS in 2021, setting the stage for strong growth in 2022. However, net losses widened to $47 million or $0.37 per share, up from a loss of $26.5 million in the same quarter last year. Aurinia had $323.7 million in cash as of June 30, 2021, supporting its commercial and R&D activities.

Aurinia Pharmaceuticals (NASDAQ: AUPH) will announce its second quarter 2021 financial results on August 5, 2021, after market close. Management will host a conference call at 4:30 p.m. EDT to discuss these results and provide a business update. Interested participants are invited to join the call by dialing +1-877-407-9170 or via an audio webcast available on the company's website.

Aurinia is focused on therapies for serious diseases, particularly lupus nephritis, and has launched LUPKYNIS™, the first FDA-approved oral therapy for this condition.